arzerra (ofatumumab) - Articles and news items

FDA approves Genmab’s ofatumumab for relapsed CLL

Industry news / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+